Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Finasteride
Drug ID BADD_D00898
Description Finasteride is a synthetic 4-azasteroid compound [L10565] and specific inhibitor of steroid Type II 5α-reductase, which is an intracellular enzyme that converts the androgen testosterone into 5α-dihydrotestosterone (DHT). It works in a similar fashion as [dutasteride], which is another 5-alpha-reductase inhibitor, by exerting antiandrogenic effects. Finasteride is an orally active drug that was first approved by the FDA in 1992 for the treatment of benign prostatic hyperplasia to improve symptoms and reduce the risk for acute urinary retention or the need for surgical procedures.[L6244,L10565] In 1998, it was approved by the FDA to treat male pattern hair loss.[L6244] Finasteride is commonly marketed under the brand names Propecia and Proscar to be used aloneo or in combination with [doxazosin], an alpha-blocker. Both benign prostatic hyperplasia and androgenic alopecia are androgen-dependent disorders that are characterized by _in situ_ high levels of DHT.[A178159] In the treatment of benign prostate hyperplasia, alpha-blockers such as [tamsulosin] and [terazosin] are also used. Compared to alpha-blockers that focus on providing the rapid relief of symptoms, 5α-reductase inhibitors aim to target the underlying disease by blocking the effects of the primary androgen involved in benign prostate hyperplasia and androgenic alopecia, thus reducing the risk for secondary complications while providing symptom control.[A2132]
Indications and Usage For the treatment of symptomatic benign prostatic hyperplasia (BPH) in men with an enlarged prostate to: Improve symptoms, reduce the risk of acute urinary retention, reduce the risk of the need for surgery including transurethral resection of the prostate. Also used for the stimulation of regrowth of hair in men with mild to moderate androgenetic alopecia (male pattern alopecia, hereditary alopecia, common male baldness).
Marketing Status Prescription; Discontinued
ATC Code D11AX10; G04CB01
DrugBank ID DB01216
KEGG ID D00321
MeSH ID D018120
PubChem ID 57363
TTD Drug ID D08IWD
NDC Product Code 68071-3380; 71335-0281; 71335-1898; 76420-074; 71335-0235; 63187-265; 14501-0013; 68645-541; 68788-6976; 65862-370; 68554-0022; 60687-428; 50090-1936; 53104-7714; 68071-4541; 68382-074; 0395-8239; 38779-2410; 71335-1530; 65862-927; 49452-3147; 62756-913; 64918-0706; 70771-1152; 71052-602; 63187-863; 43598-303; 68071-4167; 63629-8180; 65862-149; 76420-151; 71713-096; 71610-515; 68788-6875; 71335-0433; 57237-061; 76420-154; 50090-4697; 55154-8083; 71713-099; 50090-4648; 48087-0092; 55111-172; 71610-520; 64918-0422; 46144-345; 71335-1304; 16729-090; 50268-314; 70518-2287; 70518-2363; 76282-412; 51927-4847; 17856-0090; 67877-288; 51552-1470; 68071-3094; 43598-390; 55111-026; 51508-001; 68071-3306; 68071-3354; 78206-153; 50090-3942; 68071-4808; 16729-089; 53104-7549; 70518-0397; 69097-112; 31722-526; 70518-3182; 68981-021; 61919-733; 57237-062; 71335-1634; 55111-171; 35573-400; 0093-7355; 0904-6830; 67877-455; 68071-2620; 78206-152; 31722-525; 50090-1718
Synonyms Finasteride | Chibro-Proscar | Chibro Proscar | Propecia | Propeshia | MK-906 | MK 906 | MK906 | Proscar | Eucoprost
Chemical Information
Molecular Formula C23H36N2O2
CAS Registry Number 98319-26-7
SMILES CC12CCC3C(C1CCC2C(=O)NC(C)(C)C)CCC4C3(C=CC(=O)N4)C
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Oestrogen receptor positive breast cancer21.05.01.025; 16.10.01.0160.000855%Not Available
Soft tissue mass15.03.02.0190.000214%Not Available
Small intestinal bacterial overgrowth11.02.01.048; 07.19.01.0230.000321%Not Available
Bladder outlet obstruction20.03.01.0190.000428%Not Available
Spinal pain17.10.01.020; 15.02.01.008; 08.01.08.0300.000534%Not Available
Male genital atrophy21.10.05.017; 05.05.02.0100.001497%Not Available
Meniscus injury15.07.03.006; 12.04.03.0080.000748%Not Available
Invasive ductal breast carcinoma21.05.01.021; 16.10.01.0130.000214%Not Available
Fat tissue decreased08.01.03.0680.000321%Not Available
Penile contusion21.12.01.016; 12.01.15.005; 24.07.06.023; 23.03.11.0200.000214%Not Available
Genital paraesthesia17.02.06.032; 21.10.05.0160.000962%Not Available
Genital atrophy21.10.05.014; 05.05.04.0080.001069%Not Available
Fine motor skill dysfunction17.01.02.0200.000214%Not Available
Gluten sensitivity14.02.01.008; 10.01.01.031; 07.17.01.0090.000214%Not Available
Increased viscosity of upper respiratory secretion22.02.05.0390.000214%Not Available
Mental fatigue19.21.02.012; 17.03.03.0060.000214%Not Available
The 35th Page    First    Pre   35    Total 35 Pages